ACTA’s Board of Directors is responsible for the corporate governance and financial management of the organisation. Australian Clinical Trials Alliance Limited (ACN 168 693 972) is a not-for-profit public company limited by guarantee. ACTA’s Constitution can be viewed here.
ACTA Board Members
-
Prof Steve Webb MBBS MPH PhD FCICM FRACP FAHMS
ACTA Board Chair
Intensive Care Unit, Royal Perth Hospital, School of Medicine & Pharmacology, University of Western Australia.
-
Prof Christopher Reid B.A, Dip Ed, M Sc, PhD
ACTA Board Deputy Chair
Research Professor at the School of Public Health and Preventive Medicine, Monash University and the School of Population Health at Curtin University
-
Prof Meg Jardine, MBBS, PhD, FRACP
ACTA Board Director
Director, The University of Sydney NHMRC Clinical Trials Centre.
-
Ms Anne McKenzie, AM
ACTA Board Director
Manager, Community Engagement, Telethon Kids Institute
-
Prof Rachael Morton, DipAppSc, MSc(Clin Epi)(Hons), PhD
ACTA Board Director
Director, Health Economics, NHMRC Clinical Trials Centre, University of Sydney
-
Mr Kieran Schneemann
ACTA Board Director
Director of Government Affairs, AstraZeneca. Associate Director for Canteen.
-
Ian A R Wilson FCPA, AGIA, ACIS, MAICD
ACTA Board Director
Grant Finance Office, The Florey Institute of Neuroscience & Mental Health
-
Prof John Zalcberg OAM, MBBS PhD FRACP FRACMA FAHMS FAICD
ACTA Board Director
Head, Cancer Research Program, School of Public Health & Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University; and Consultant Medical Oncologist, Peter MacCallum Cancer Centre.
